Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to … Read full Trend Edge analysis →
| Current Price | $28.67 |
|---|---|
| Market Cap | $499M |
| Float | 893K |
| Shares Outstanding | 16.2M |
| Price/Sales (TTM) | 13.74 |
| Profit Margin | -98.48% |
| Operating Margin (TTM) | -556.52% |
| Revenue (TTM) | $36.3M |
| Dividend Rate | None |
| Year | Revenue | Net Income | Gross Profit | EBITDA |
|---|---|---|---|---|
| 2024 | $27.4M | -$47.8M | N/A | N/A |
| 2025 | $51.2M | -$21.8M | N/A | N/A |
| Quarter | Revenue | Net Income |
|---|---|---|
| Mar 2025 | $17.1M | -$3.4M |
| Mar 2026 | $2.2M | -$17.3M |
| Insider Ownership | 10.7% |
|---|---|
| Institutional Ownership | 49.4% |
| Short Float | 31.9% |
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
| Timeframe | SMA | Value | Trend Context |
|---|---|---|---|
| Weekly | 10-Week SMA | $0.00 | Near-term / short-term trend |
| Weekly | 40-Week SMA | $0.00 | Medium-term trend |
| Weekly | 80-Week SMA | $0.00 | Cyclical trend (business cycle) |
| Weekly | 200-Week SMA | $0.00 | Secular trend (multi-year) |
| Monthly | 10-Month SMA | $0.00 | Near-term monthly trend |
| Monthly | 20-Month SMA | $0.00 | Medium-term monthly trend |
| Monthly | 40-Month SMA | $0.00 | Secular monthly trend |
Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Volume shelf data not available.
| Timeframe | Avg Return | Median | Win Rate | Best | Worst |
|---|---|---|---|---|---|
| Gap | 0.32% | 0.32% | 100.00% | 0.32% | 0.32% |
| 1 Day | -0.29% | -0.29% | 0.00% | -0.29% | -0.29% |
| 1 Week | N/A | N/A | N/A | N/A | N/A |
| 2 Weeks | N/A | N/A | N/A | N/A | N/A |
| 1 Month | N/A | N/A | N/A | N/A | N/A |
Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).
Institutional holder breakdown coming soon.
Total institutional ownership: 49.4%
Total insider ownership: 10.7%
| Total Filings | 6 |
|---|---|
| Net Value | +$84,990 |
| Net Shares Change | 8,177,279 |
| % of Float | 916.1% |
| C-Suite Filings | 2 |
| Clusters Detected | 1 |
| Name | Title | Net Value | Filings | Activity |
|---|---|---|---|---|
| Aghazadeh Behzad | +$36.3M | 1 | 1 buy | |
| ORBIMED ADVISORS LLC | +$15.0M | 1 | 1 buy | |
| GORDON CARL L | +$15.0M | 1 | 1 buy | |
| AH Bio Fund II, L.P. | +$5.0M | 1 | 1 buy | |
| Lucas Svetlana | Chief Business Officer | +$45,000 | 1 | 1 buy |
| Parrot David | Chief Financial Officer | +$39,990 | 1 | 1 buy |
| Period | Filings | Insiders | Net Value | Seniority |
|---|---|---|---|---|
| 2026-07-27 – 2026-07-29 | 6 | 6 | +$71.3M | 2 C-suite |
| Date | Insider | Title | Net Value | Price After |
|---|---|---|---|---|
| 2026-07-27 | Parrot David | Chief Financial Officer | +$39,990 | Transaction at $15.00, now +91.1% |
| 2026-07-27 | Lucas Svetlana | Chief Business Officer | +$45,000 | Transaction at $15.00, now +91.1% |
| 2026-07-29 | ORBIMED ADVISORS LLC | +$15.0M | Transaction at $15.00, now +91.1% | |
| 2026-07-29 | GORDON CARL L | +$15.0M | Transaction at $15.00, now +91.1% | |
| 2026-07-28 | Aghazadeh Behzad | +$36.3M | Transaction at $15.16, now +89.1% | |
| 2026-07-29 | AH Bio Fund II, L.P. | +$5.0M | Transaction at $15.00, now +91.1% |
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Scribe Therapeutics Inc. Common Stock (SCTX) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.
Get the full AI Consult analysis for SCTX on Trend Edge →